BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 29, Issue 37
This Article
Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
  • Total Article Views (6959)
All Articles published online
The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-2) series.
Item 
Count 
PDF93
WORD37
HTML5205
Figures (1-6)267
Tables (1-2)146
 Sum=5748
Featured Article
The chart showing Browse series, Download series.
Item 
Count 
Browse232
Download324
 Sum=556
Publishing Process of This Article
The chart showing Browse series, Download series.
Item 
Count 
Browse117
Download220
 Sum=337
Oct 7, 2023 (publication date) through May 23, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef
For: Zhu K, Kakkar R, Chahal D, Yoshida EM, Hussaini T. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease. World J Gastroenterol 2023; 29(37): 5327-5338 [PMID: 37899788 DOI: 10.3748/wjg.v29.i37.5327]
URL: https://www.wjgnet.com/1007-9327/full/v29/i37/5327.htm
Number Citing Articles
1
Antonio Saviano, Natascha Roehlen, Thomas F. Baumert. Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma. Seminars in Liver Disease 2024;  doi: 10.1055/s-0044-1785646
2
Mohamed Mahmoud Marey, Mohamed Belal, Abdelaziz A. Awad, Eslam Mohammed Rabea, Malak A. Hassan, Ahmed W. Abbas, Abdulqadir J. Nashwan. Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials. Clinics and Research in Hepatology and Gastroenterology 2024; 48(6): 102357 doi: 10.1016/j.clinre.2024.102357
3
Mohit Kehar, Samar H. Ibrahim, Charina M. Ramirez, Saista Asif Amin, Tamir Diamond, Saeed Mohammad. Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction‐associated steatotic liver disease. Journal of Pediatric Gastroenterology and Nutrition 2024;  doi: 10.1002/jpn3.12236
4
Matthew Peverelle, Jonathan Ng, James Peverelle, Ryan D. Hirsch, Adam Testro. Liver decompensation after rapid weight loss from semaglutide in a patient with non-alcoholic steatohepatitis -associated cirrhosis. World Journal of Gastroenterology 2023; 29(47): 6165-6167 doi: 10.3748/wjg.v29.i47.6165
5
Yue-Hua Yin, Li-Xuan Sang, Bing Chang. Potential therapeutic targets for nonalcoholic fatty liver disease: Glucagon-like peptide 1. World Journal of Gastroenterology 2023; 29(48): 6235-6238 doi: 10.3748/wjg.v29.i48.6235
6
Megan O. Bensignor, Silva Arslanian, Mary Ellen Vajravelu. Semaglutide for management of obesity in adolescents: efficacy, safety, and considerations for clinical practice. Current Opinion in Pediatrics 2024;  doi: 10.1097/MOP.0000000000001365
7
Hong-Tai Tzeng, Wei-Chia Lee. Impact of Transgenerational Nutrition on Nonalcoholic Fatty Liver Disease Development: Interplay between Gut Microbiota, Epigenetics and Immunity. Nutrients 2024; 16(9): 1388 doi: 10.3390/nu16091388
Write to the Help Desk
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345